In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate (ADC) for breast cancer, hoping to build on the success of a partnership that already spawned a ...

The prevalence of type 2 diabetes is rising globally, with a disproportionate impact on individuals in low-income and ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

Read Next: AstraZeneca Aims to Restor TOKYO & BASKING RIDGE, N.J., January 13, 2025--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire ...

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...

Coming in first on the list of Top 25 Pharma Companies US Rx is AbbVie, reaching $41,857m in US Rx revenue in 2023 and ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...

The market for PDTs in oncology is projected to experience substantial growth in the coming years. This growth is driven by a rising number of patien ...